Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

The best fit for enzalutamide in metastatic prostate cancer

Nature Reviews Clinical Oncology volume 11, pages 504–506 (2014)Cite this article

Subjects

The PREVAIL trial compared enzalutamide and placebo in patients with metastatic castration-resistant prostate cancer who had not received prior chemotherapy, demonstrating an improvement in overall survival and other clinical, radiographic, and biochemical outcomes. Herein, the implications of these data in the rapidly changing landscape of metastatic prostate cancer therapy are discussed.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. http://dox.doi.org/10.1056/NEJMoa1405095.

  2. Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787–790 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).

    Article  CAS  PubMed  Google Scholar 

  4. Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).

    CAS  PubMed  Google Scholar 

  5. Cheng, H. H. et al. The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC [abstract]. J. Clin. Oncol. 32 (Suppl.), 18 (2014).

    Article  Google Scholar 

  6. Noonan, K. L. et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann. Oncol. 24, 1802–1807 (2013).

    Article  CAS  PubMed  Google Scholar 

  7. Loriot, Y. et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann. Oncol. 24, 1807–1812 (2013).

    Article  CAS  PubMed  Google Scholar 

  8. Sweeney, C. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial [abstract]. J. Clin. Oncol. 32 (Suppl.), LBA2 (2014).

    Article  Google Scholar 

  9. Antonarakis, E. S. et al. Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J. Clin. Oncol. 32 (Suppl.), 5001 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, 91010, CA, USA

    Sumanta K. Pal

  2. Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, 70112, LA, USA

    Oliver Sartor

Authors
  1. Sumanta K. Pal
    View author publications

    Search author on:PubMed Google Scholar

  2. Oliver Sartor
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Sumanta K. Pal.

Ethics declarations

Competing interests

S.K.P. has received honoraria from Medivation. O.S. is a consultant for Medivation/Astellas, and a consultant and investigator for Bayer, Dendreon, Janssen, and Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pal, S., Sartor, O. The best fit for enzalutamide in metastatic prostate cancer. Nat Rev Clin Oncol 11, 504–506 (2014). https://doi.org/10.1038/nrclinonc.2014.128

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2014.128

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer